VEPESID Side Effects

6992997-0 | Stomatitis
on Sep 10, 2010 Male patient from JAPAN , 50 years of age, was diagnosed with diffuse large b-cell lymphoma, prophylaxis and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: stomatitis. Vepesid dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), POLAPREZINC (View Polaprezinc Review and Polaprezinc Label ). Patient was hospitalized.

6893711-X | Delirium, Febrile Neutropenia, Pulmonary Alveolar Haemorrhage, Pulmonary Oedema, Respiratory Failure, Sepsis
Patient was taking Vepesid (View Usage). Patient had the following side effects: delirium, febrile neutropenia, pulmonary alveolar haemorrhage, pulmonary oedema, respiratory failure, sepsis (What is sepsis?) on Jul 22, 2010 from JAPAN Additional patient health information: Female patient , child 10 years of age, was diagnosed with ewing's sarcoma and. Vepesid dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

6860858-3 | Overdose
Adverse event was reported on Jul 16, 2010 by a Male patient taking Vepesid (View Usage) (Dosage: 8 Days Dosage Over A 3 Days Period) was diagnosed with hodgkin's disease (What is hodgkin's disease?) and. Location: UNITED KINGDOM , 32 years of age, After Vepesid was administered, patient had the following side effects: overdose. During the same period patient was treated with CCNU (View Ccnu Review and Ccnu Label ).

6855210-0 | Arrhythmia, Circulatory Collapse
on Jul 15, 2010 Male patient from SWEDEN , 70 years of age, was diagnosed with acute leukaemia, atrial fibrillation (What is atrial fibrillation?) and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: arrhythmia (What is arrhythmia?), circulatory collapse. Vepesid dosage: . During the same period patient was treated with SOTALOL (View Sotalol Review and Sotalol Label ), AMEKRIN (View Amekrin Review and Amekrin Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ).


6848573-3 | Overdose
on Jul 14, 2010 Male patient from UNITED KINGDOM , 32 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Vepesid (View Usage). Patient had the following side effects: overdose. Vepesid dosage: 8 Days Dosage Over A 3 Days Period. During the same period patient was treated with CCNU (View Ccnu Review and Ccnu Label ).

6847859-6 | Anaemia, Haemoptysis
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: anaemia, haemoptysis on Jul 12, 2010 from JAPAN Additional patient health information: Female patient , 58 years of age, . Vepesid dosage: . During the same period patient was treated with CARBOPLATIN (Formulation: Carboplatin Nx) (View Carboplatin Review and Carboplatin Label ).

6835562-8 | Azoospermia, Varicocele
Adverse event was reported on Jul 07, 2010 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with seminoma and. Location: JAPAN , 32 years of age, weighting 143.3 lb, Patient experienced the following unwanted or unexpected effects: azoospermia, varicocele. During the same period patient was treated with RANDA (View Randa Review and Randa Label ), BLEO (View Bleo Review and Bleo Label ).

6818859-7 | Azoospermia, Varicocele
on Jun 30, 2010 Male patient from JAPAN , 32 years of age, was diagnosed with seminoma and was treated with Vepesid (View Usage). Patient had the following side effects: azoospermia, varicocele. Vepesid dosage: . During the same period patient was treated with RANDA (View Randa Review and Randa Label ), BLEO (View Bleo Review and Bleo Label ).

6790290-2 | Pneumonia, Pneumothorax
on Jun 16, 2010 Male patient from JAPAN , 78 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: pneumonia (What is pneumonia?), pneumothorax. Vepesid dosage: . Patient was hospitalized.

6770282-X | Disseminated Intravascular Coagulation, Subdural Haemorrhage, Tumour Lysis Syndrome
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: disseminated intravascular coagulation, subdural haemorrhage, tumour lysis syndrome on Jun 07, 2010 from JAPAN Additional patient health information: Female patient , 69 years of age, was diagnosed with diffuse large b-cell lymphoma and. Vepesid dosage: . During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6762045-6 | Atelectasis, Bone Marrow Failure, Lung Disorder, Pneumonia, Pulmonary Alveolar Haemorrhage, Respiratory Failure
Adverse event was reported on Jun 03, 2010 by a Male patient taking Vepesid (View Usage) (Dosage: Days 1-3) . Location: JAPAN , 54 years of age, Patient had the following side effects: atelectasis, bone marrow failure, lung disorder, pneumonia (What is pneumonia?), pulmonary alveolar haemorrhage, respiratory failure. During the same period patient was treated with CARBOPLATIN (On Day 1) (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.

6744470-2 | Malaise, Stomatitis
on May 24, 2010 Male patient from ITALY , 51 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: malaise, stomatitis. Vepesid dosage: . During the same period patient was treated with BICNU (View Bicnu Review and Bicnu Label ), CYTARABINE (Aracytin 500mg/10ml Powder And Solvent For Injectable Solution,) (View Cytarabine Review and Cytarabine Label ), ALKERAN (Alkeran 50mg/10ml Powder And Solvent For Injectable Solution) (View Alkeran Review and Alkeran Label ), ZOVIRAX (400 Mg Oral Tabs) (View Zovirax Review and Zovirax Label ), ISENTRESS (400 Mg Film Coated Oral Tabs) (View Isentress Review and Isentress Label ), NORVIR (100 Mg Soft Oral Caps) (View Norvir Review and Norvir Label ), PREZISTA (300 Mg Film Coated Oral Tabs) (View Prezista Review and Prezista Label ), CELSENTRI (150mg Film Coated Oral Tabs) (View Celsentri Review and Celsentri Label ). Patient was hospitalized.

6744469-6 | Pneumonitis, Pseudomonal Sepsis
on May 24, 2010 Female patient from ITALY , 59 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonitis, pseudomonal sepsis. Vepesid dosage: . During the same period patient was treated with BICNU PWDR FOR INJ (Carmustin Injectable Solution) (View Bicnu Pwdr For Inj Review and Bicnu Pwdr For Inj Label ), CYTARABINE (Aracytin 500mg/10ml Powder And Solvent For Injectable Solution) (View Cytarabine Review and Cytarabine Label ), ALKERAN (Alkeran 50mg/10ml Powder And Solvent For Injectable Solution) (View Alkeran Review and Alkeran Label ), DECADRONE (1df: 4mg/1ml Injectable Solution) (View Decadrone Review and Decadrone Label ), LEVOXACIN (500mg Film Coated Oral Tabs) (View Levoxacin Review and Levoxacin Label ), MEPRAL (20mg Modified Release Oral Caps) (View Mepral Review and Mepral Label ), SPORANOX (Sporanox 100mg Oral Caps) (View Sporanox Review and Sporanox Label ), ZOVIRAX (400mg Oral Caps) (View Zovirax Review and Zovirax Label ). Patient was hospitalized.

6668598-0 | Malaise, Stomatitis
Patient was taking Vepesid (View Usage). Patient had the following side effects: malaise, stomatitis on Apr 01, 2010 from ITALY Additional patient health information: Male patient , 51 years of age, was diagnosed with non-hodgkin's lymphoma and. Vepesid dosage: . During the same period patient was treated with CARMUSTINE (View Carmustine Review and Carmustine Label ), CYTARABINE (Aracytin 500mg/10ml Powder And Solvent For Injectable Solution,) (View Cytarabine Review and Cytarabine Label ), ALKERAN (Alkeran 50mg/10ml Powder And Solvent For Injectable Solution) (View Alkeran Review and Alkeran Label ), ZOVIRAX (400 Mg Oral Tabs) (View Zovirax Review and Zovirax Label ), ISENTRESS (400 Mg Film Coated Oral Tabs) (View Isentress Review and Isentress Label ), NORVIR (100 Mg Soft Oral Caps) (View Norvir Review and Norvir Label ), PREZISTA (300 Mg Film Coated Oral Tabs) (View Prezista Review and Prezista Label ), CELSENTRI (150mg Film Coated Oral Tabs) (View Celsentri Review and Celsentri Label ). Patient was hospitalized.

6668597-9 | Pneumonitis, Pseudomonal Sepsis
Adverse event was reported on Apr 01, 2010 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with non-hodgkin's lymphoma and. Location: ITALY , 59 years of age, After Vepesid was administered, patient had the following side effects: pneumonitis, pseudomonal sepsis. During the same period patient was treated with BICNU PWDR FOR INJ (Carmustin Injectable Solution) (View Bicnu Pwdr For Inj Review and Bicnu Pwdr For Inj Label ), CYTARABINE (Aracytin 500mg/10ml Powder And Solvent For Injectable Solution) (View Cytarabine Review and Cytarabine Label ), ALKERAN (Alkeran 50mg/10ml Powder And Solvent For Injectable Solution) (View Alkeran Review and Alkeran Label ), DECADRONE (1df: 4mg/1ml Injectable Solution) (View Decadrone Review and Decadrone Label ), LEVOXACIN (500mg Film Coated Oral Tabs) (View Levoxacin Review and Levoxacin Label ), MEPRAL (20mg Modified Release Oral Caps) (View Mepral Review and Mepral Label ), SPORANOX (Sporanox 100mg Oral Caps) (View Sporanox Review and Sporanox Label ), ZOVIRAX (400mg Oral Caps) (View Zovirax Review and Zovirax Label ). Patient was hospitalized.

6660577-2 | Malignant Neoplasm Progression, Neutropenia, Pneumonitis
on Mar 26, 2010 Male patient from ITALY , 57 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: malignant neoplasm progression, neutropenia, pneumonitis. Vepesid dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), ENDOXAN BAXTER (Endoxan Baxter 1 G Powder For Injectable Solution Every 15 Days) (View Endoxan Baxter Review and Endoxan Baxter Label ), DARBEPOETIN ALFA (View Darbepoetin Alfa Review and Darbepoetin Alfa Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ).

6657318-1 | Acute Respiratory Failure
on Mar 18, 2010 Male patient from JAPAN , 66 years of age, was treated with Vepesid (View Usage). Patient had the following side effects: acute respiratory failure. Vepesid dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6657313-2 | Acute Respiratory Failure
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: acute respiratory failure on Mar 18, 2010 from JAPAN Additional patient health information: Male patient , 64 years of age, . Vepesid dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6634160-9 | Overdose
Adverse event was reported on Sep 24, 2007 by a Male patient taking Vepesid (View Usage) (Dosage: 8 Days Dosage Over A 3 Days Period) . Location: UNITED KINGDOM , 32 years of age, Patient experienced the following unwanted or unexpected effects: overdose. During the same period patient was treated with CCNU (View Ccnu Review and Ccnu Label ).

6580975-5 | Hepatitis B, Malignant Neoplasm Progression
on Feb 04, 2010 Female patient from JAPAN , 76 years of age, weighting 92.59 lb, was diagnosed with adult t-cell lymphoma/leukaemia and was treated with Vepesid (View Usage). Patient had the following side effects: hepatitis b (What is hepatitis b?), malignant neoplasm progression. Vepesid dosage: . During the same period patient was treated with PREDONINE (View Predonine Review and Predonine Label ).

6541024-8 | Hepatitis B
on Jan 12, 2010 Female patient from JAPAN , 76 years of age, was diagnosed with adult t-cell lymphoma/leukaemia and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: hepatitis b (What is hepatitis b?). Vepesid dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), STEROIDS (View Steroids Review and Steroids Label ), PIRARUBICIN (View Pirarubicin Review and Pirarubicin Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6526512-2 | Chronic Graft Versus Host Disease, Cytomegalovirus Infection, Leukoplakia Oral, Oesophageal Squamous Cell Carcinoma, Pneumocystis Jiroveci Pneumonia, Scleroderma
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: chronic graft versus host disease, cytomegalovirus infection (What is cytomegalovirus infection?), leukoplakia oral, oesophageal squamous cell carcinoma, pneumocystis jiroveci pneumonia, scleroderma (What is scleroderma?) on Dec 25, 2009 from JAPAN Additional patient health information: Male patient , 27 years of age, was diagnosed with acute lymphocytic leukaemia, prophylaxis and. Vepesid dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6445097-2 | Cytomegalovirus Infection, Transplant Failure
Adverse event was reported on Nov 09, 2009 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with hepatitis fulminant and. Location: JAPAN , child 4 years of age, Patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), transplant failure.

6309655-8 | Bone Sarcoma
on Aug 06, 2009 Male patient from JAPAN , child 11 years of age, was diagnosed with medulloblastoma and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: bone sarcoma. Vepesid dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CISPLATIN (Form = Inj) (View Cisplatin Review and Cisplatin Label ), VINCRISTINE SULFATE (Form = Inj) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), THIOTEPA (Form = Inj) (View Thiotepa Review and Thiotepa Label ).

6303374-X | Histiocytosis, Neutropenia, Respiratory Failure
on Jul 30, 2009 Male patient from GERMANY , 31 years of age, was diagnosed with langerhans' cell granulomatosis and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: histiocytosis, neutropenia, respiratory failure. Vepesid dosage: . During the same period patient was treated with HYDREA (View Hydrea Review and Hydrea Label ), PARAPLATIN (View Paraplatin Review and Paraplatin Label ), FUNGIZONE (View Fungizone Review and Fungizone Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISOLONE (High Dosages (30-40 Mg/m^2) Last 6 Months.) (View Prednisolone Review and Prednisolone Label ), ONCOVIN (View Oncovin Review and Oncovin Label ).

6298193-7 | Interstitial Lung Disease
Patient was taking Vepesid (View Usage). Patient had the following side effects: interstitial lung disease on Jul 31, 2009 from JAPAN Additional patient health information: Male patient , 40 years of age, was diagnosed with testis cancer and. Vepesid dosage: Cycle 1 On 17nov08:120mg/day X5;route Dr Cyc 2 Unk-12dec08:85mg/day X5;total Dose 1025 Mg. During the same period patient was treated with RANDA (Cycle 1 On 17nov08: 25mg/day X5;route Dr Cyc2 Unk-12dec08:17mg/day X5;total Dose 210mg) (View Randa Review and Randa Label ), BLEO (Cycle 1 On 18nov08: 12.5mg/day X2;route Dr Cycle 2 On Unk-23dec08: 8.5mg/day X3 49.5mg(total Dose)) (View Bleo Review and Bleo Label ), NASEA (Route Dr) (View Nasea Review and Nasea Label ), DECADRON (Route Dr) (View Decadron Review and Decadron Label ), SERENACE (Route Dr) (View Serenace Review and Serenace Label ), GASTER (Route Dr) (View Gaster Review and Gaster Label ), INSULIN (View Insulin Review and Insulin Label ).

6293547-7 | Cerebellar Haemorrhage
Adverse event was reported on Jul 24, 2009 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with natural killer-cell leukaemia and. Location: JAPAN , 31 years of age, After Vepesid was administered, patient had the following side effects: cerebellar haemorrhage. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6292114-9 | Gastrointestinal Haemorrhage, Retinal Haemorrhage, Vomiting
on Jul 24, 2009 Male patient from JAPAN , 21 years of age, was diagnosed with lymphoproliferative disorder, natural killer-cell leukaemia and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: gastrointestinal haemorrhage, retinal haemorrhage, vomiting. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ADRIACIN (View Adriacin Review and Adriacin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), EPIRUBICIN HCL (View Epirubicin Hcl Review and Epirubicin Hcl Label ).

6266111-3 | Gastrointestinal Haemorrhage, Retinal Haemorrhage, Vomiting
on Jul 08, 2009 Male patient from JAPAN , 21 years of age, was diagnosed with lymphoproliferative disorder and was treated with Vepesid (View Usage). Patient had the following side effects: gastrointestinal haemorrhage, retinal haemorrhage, vomiting. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ADRIACIN (View Adriacin Review and Adriacin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), EPIRUBICIN HCL (View Epirubicin Hcl Review and Epirubicin Hcl Label ).

6253236-1 | Apnoea, Asphyxia, Blood Pressure Increased, Clonus, Cyanosis Central, Loss Of Consciousness, Micturition Disorder
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: apnoea, asphyxia, blood pressure increased, clonus, cyanosis central, loss of consciousness, micturition disorder on Jun 30, 2009 from BULGARIA Additional patient health information: Male patient , 66 years of age, weighting 132.3 lb, was diagnosed with bronchial carcinoma and. Vepesid dosage: . During the same period patient was treated with ALOXI (Injection Form) (View Aloxi Review and Aloxi Label ), DEXASONE (Injection Form) (View Dexasone Review and Dexasone Label ).

6179754-2 | Asphyxia, Clonus, Cyanosis Central, Loss Of Consciousness, Micturition Disorder
Adverse event was reported on Apr 29, 2009 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with bronchial carcinoma and. Location: BULGARIA , 66 years of age, weighting 132.3 lb, Patient experienced the following unwanted or unexpected effects: asphyxia, clonus, cyanosis central, loss of consciousness, micturition disorder. During the same period patient was treated with ALOXI (Injection Form) (View Aloxi Review and Aloxi Label ), DEXASONE (View Dexasone Review and Dexasone Label ).

6134514-3 | Interstitial Lung Disease
on Mar 24, 2009 Male patient from JAPAN , 40 years of age, was diagnosed with testis cancer and was treated with Vepesid (View Usage). Patient had the following side effects: interstitial lung disease. Vepesid dosage: Cycle 1 On 17nov08:120mg/day X5;route Dr Cyc 2 Unk-12dec08:85mg/day X5;total Dose 1025 Mg. During the same period patient was treated with RANDA (Cycle 1 On 17nov08: 25mg/day X5;route Dr Cyc2 Unk-12dec08:17mg/day X5;total Dose 210mg) (View Randa Review and Randa Label ), BLEO (Cycle 1 On 18nov08: 12.5mg/day X2;route Dr Cycle 2 On Unk-23dec08: 8.5mg/day X3 49.5mg(total Dose)) (View Bleo Review and Bleo Label ), NASEA (Route Dr) (View Nasea Review and Nasea Label ), DECADRON (Route Dr) (View Decadron Review and Decadron Label ), SERENACE (Route Dr) (View Serenace Review and Serenace Label ), GASTER (Route Dr) (View Gaster Review and Gaster Label ), INSULIN (View Insulin Review and Insulin Label ).

6108818-4 | Interstitial Lung Disease
on Mar 05, 2009 Male patient from JAPAN , 40 years of age, was diagnosed with testis cancer and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: interstitial lung disease. Vepesid dosage: Cycle 1 On 17nov08: 120mg/day X5 Cycle 2 From Unk-12dec08: 85mg/day X5. During the same period patient was treated with RANDA (Cycle 1 On 17nov08: 25mg/day X5 Cycle 2 From Unk-12dec08: 17mg/day X5) (View Randa Review and Randa Label ), BLEO (Cycle 1 On 18nov08: 12mg/day X2 Cycle 2 On Unk-23dec08: 8.5mg/day X2 Total Dose: 49.5mg) (View Bleo Review and Bleo Label ).

6088681-0 | Paraparesis
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: paraparesis on Feb 20, 2009 from POLAND Additional patient health information: Female patient , 80 years of age, was diagnosed with ovarian cancer and. Vepesid dosage: .

6086559-X | Confusional State
Adverse event was reported on Feb 18, 2009 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with pineal parenchymal neoplasm malignant and. Location: JAPAN , 16 years of age, Patient had the following side effects: confusional state. During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6056351-0 | Acute Respiratory Distress Syndrome
on Jan 20, 2009 Male patient from JAPAN , child 7 years of age, was diagnosed with acute myeloid leukaemia and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: acute respiratory distress syndrome. Vepesid dosage: From Unk-unk From 02nov1999-unk:5days. During the same period patient was treated with CYTARABINE (Unk-unk 02nov1999/unk) (View Cytarabine Review and Cytarabine Label ), NOVANTRONE (View Novantrone Review and Novantrone Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ). Patient was hospitalized.

6054722-X | Liver Disorder, Lung Infection, Neoplasm, Neutropenia, Respiratory Failure
on Jan 21, 2009 Female patient from JAPAN , 36 years of age, was diagnosed with histiocytosis haematophagic, bronchopulmonary aspergillosis, pneumonia staphylococcal, neutropenia, pneumonia bacterial and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: liver disorder, lung infection, neoplasm, neutropenia, respiratory failure. Vepesid dosage: 160mg On 7jan08. During the same period patient was treated with VFEND (View Vfend Review and Vfend Label ), ZYVOX (View Zyvox Review and Zyvox Label ), PREDONINE (View Predonine Review and Predonine Label ), GRAN (View Gran Review and Gran Label ), MEROPEN (View Meropen Review and Meropen Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), BLOOD HUMAN (View Blood Human Review and Blood Human Label ), ADRENAL STEROIDS (View Adrenal Steroids Review and Adrenal Steroids Label ).

6029700-7 | Liver Disorder, Lung Infection, Neoplasm, Neutropenia, Respiratory Failure
Patient was taking Vepesid (View Usage). Patient had the following side effects: liver disorder, lung infection, neoplasm, neutropenia, respiratory failure on Jan 06, 2009 from JAPAN Additional patient health information: Female patient , 36 years of age, was diagnosed with histiocytosis haematophagic, bronchopulmonary aspergillosis, pneumonia staphylococcal, neutropenia, pneumonia bacterial and. Vepesid dosage: 160mg On 7jan08. During the same period patient was treated with ADRENAL STEROIDS (View Adrenal Steroids Review and Adrenal Steroids Label ), VFEND (View Vfend Review and Vfend Label ), ZYVOX (View Zyvox Review and Zyvox Label ), PREDONINE (View Predonine Review and Predonine Label ), GRAN (View Gran Review and Gran Label ), MEROPEN (View Meropen Review and Meropen Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ).

6012902-3 | Liver Disorder, Lung Infection, Neoplasm, Neutropenia, Respiratory Failure
Adverse event was reported on Dec 12, 2008 by a Female patient taking Vepesid (View Usage) (Dosage: 160mg On 7jan08) was diagnosed with histiocytosis haematophagic, bronchopulmonary aspergillosis, pneumonia staphylococcal, neutropenia, pneumonia bacterial and. Location: JAPAN , 36 years of age, After Vepesid was administered, patient had the following side effects: liver disorder, lung infection, neoplasm, neutropenia, respiratory failure. During the same period patient was treated with ADRENAL STEROIDS (View Adrenal Steroids Review and Adrenal Steroids Label ), VFEND (View Vfend Review and Vfend Label ), ZYVOX (View Zyvox Review and Zyvox Label ), PREDONINE (View Predonine Review and Predonine Label ), GRAN (View Gran Review and Gran Label ), MEROPEN (View Meropen Review and Meropen Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ).

6012889-3 | Interstitial Lung Disease
on Dec 12, 2008 Female patient from JAPAN , 22 years of age, was diagnosed with malignant mediastinal neoplasm and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease. Vepesid dosage: . During the same period patient was treated with BRIPLATIN (View Briplatin Review and Briplatin Label ), PARAPLATIN (View Paraplatin Review and Paraplatin Label ), IFOMIDE (View Ifomide Review and Ifomide Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ).

5988447-3 | Lung Adenocarcinoma
on Dec 05, 2008 Male patient from JAPAN , 65 years of age, was treated with Vepesid (View Usage). Patient had the following side effects: lung adenocarcinoma. Vepesid dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), RANDA (View Randa Review and Randa Label ).

5978256-3 | Dyspnoea, Liver Disorder, Neoplasm
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: dyspnoea, liver disorder, neoplasm on Dec 01, 2008 from JAPAN Additional patient health information: Female patient , 36 years of age, was diagnosed with histiocytosis haematophagic and. Vepesid dosage: . During the same period patient was treated with ADRENAL STEROIDS (View Adrenal Steroids Review and Adrenal Steroids Label ).

5955253-5 | Cardiac Failure, Haemolytic Uraemic Syndrome, Infection, Malignant Neoplasm Progression, Multi-organ Failure
Adverse event was reported on Nov 12, 2008 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with neuroblastoma recurrent and. Location: JAPAN , child 4 years of age, Patient experienced the following unwanted or unexpected effects: cardiac failure, haemolytic uraemic syndrome, infection (What is infection?), malignant neoplasm progression, multi-organ failure. During the same period patient was treated with PARAPLATIN (View Paraplatin Review and Paraplatin Label ), MELPHALAN (View Melphalan Review and Melphalan Label ).

5941721-9 | Burkitt's Lymphoma
on Oct 30, 2008 Male patient from JAPAN , 66 years of age, was treated with Vepesid (View Usage). Patient had the following side effects: burkitt's lymphoma. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), PIRARUBICIN HCL (View Pirarubicin Hcl Review and Pirarubicin Hcl Label ), IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

5933000-0 | Gastrointestinal Haemorrhage
on Oct 22, 2008 Male patient from JAPAN , 21 years of age, was diagnosed with lymphoproliferative disorder and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: gastrointestinal haemorrhage. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ADRIACIN (View Adriacin Review and Adriacin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), EPIRUBICIN HCL (View Epirubicin Hcl Review and Epirubicin Hcl Label ).

5932241-6 | Mycosis Fungoides Recurrent, Myelodysplastic Syndrome
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: mycosis fungoides recurrent, myelodysplastic syndrome on Oct 20, 2008 from POLAND Additional patient health information: Male patient , 24 years of age, was diagnosed with t-cell lymphoma and. Vepesid dosage: 4 Cycles.. During the same period patient was treated with CISPLATIN (4 Cycles.) (View Cisplatin Review and Cisplatin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), SOLU MEDROL (4 Cycles.) (View Solu-medrol Review and Solu-medrol Label ), ARA C (4 Cycles.) (View Ara-c Review and Ara-c Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), ENCORTON (View Encorton Review and Encorton Label ).

5927772-9 |
Adverse event was reported on Oct 20, 2008 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with leukaemia and. Location: JAPAN , 37 years of age, . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ).

5921153-X | Accidental Needle Stick, Erythema, Pain In Extremity, Swelling
on May 16, 2008 Female patient from UNITED STATES , weighting 134.5 lb, was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: accidental needle stick, erythema, pain in extremity, swelling. Vepesid dosage: .

5910150-6 | Blood Pressure Decreased, Bone Marrow Failure, Disseminated Intravascular Coagulation, Infection, Multi-organ Failure
on Oct 03, 2008 Male patient from JAPAN , 79 years of age, was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, bone marrow failure, disseminated intravascular coagulation, infection (What is infection?), multi-organ failure. Vepesid dosage: Initiated On 01aug08: 50 Mg/m2 Thrice Monthly.. During the same period patient was treated with CARBOMERCK (1 Dosage Form = Auc 4.5) (View Carbomerck Review and Carbomerck Label ).

5893457-0 | Blood Pressure Decreased, Bone Marrow Failure, Hepatic Failure, Renal Failure
Patient was taking Vepesid (View Usage). Patient had the following side effects: blood pressure decreased, bone marrow failure, hepatic failure, renal failure on Sep 19, 2008 from JAPAN Additional patient health information: Male patient , 79 years of age, . Vepesid dosage: Initiated On 01aug08: 50 Mg/m2 Thrice Monthly.. During the same period patient was treated with CARBOMERCK (1 Dosage Form = Auc 4.5) (View Carbomerck Review and Carbomerck Label ).